Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F Thompson

Showing results (461-470 of 569) with videos related to

Pageof 57
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 8, 2022
Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomesMary-Ann El Sharouni, Richard A Scolyer, Carla H van Gils, et al.
Journal of the American Academy of Dermatology|September 7, 2024
Comparison of clinicopathological features and treatment outcomes for cutaneous melanomas of the head and neck and melanomas arising at other sites: Implications for systemic therapyAndrew T Li, Jessie X Xu, Tyler R Blah, et al.
Cancers|December 5, 2019
Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic MelanomaRussell J Diefenbach, Jenny H Lee, Dario Strbenac, et al.
Annals of Surgical Oncology|May 27, 2024
Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 MelanomasAlec A Winder, Zoe Boyer, Sydney Ch'ng, et al.
Annals of Surgical Oncology|December 22, 2019
Regional Node Basin Recurrence in Melanoma Patients: More Common After Node Dissection for Macroscopic Rather than Clinically Occult Nodal DiseaseAbhineet Uppal, Stacey Stern, John F Thompson, et al.
Oncotarget|October 22, 2014
TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cellsSelina K Sutton, Jessica Koach, Owen Tan, et al.
The Journal of Investigative Dermatology|August 31, 2012
BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanomaGraham J Mann, Gulietta M Pupo, Anna E Campain, et al.
CA: a Cancer Journal for Clinicians|October 14, 2017
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manualJeffrey E Gershenwald, Richard A Scolyer, Kenneth R Hess, et al.
Melanoma Research|May 17, 2022
Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spreadAndrew T Li, Jia Miin Yip, Harsham Choksi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2018
CD103<sup>+</sup> Tumor-Resident CD8<sup>+</sup> T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 TreatmentJarem Edwards, James S Wilmott, Jason Madore, et al.
Pageof 57

Showing results (461-470 of 569) with videos related to

Sort By:
Pageof 57
European Journal of Cancer (Oxford, England : 1990)|March 8, 2022
Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomesMary-Ann El Sharouni, Richard A Scolyer, Carla H van Gils, et al.
Journal of the American Academy of Dermatology|September 7, 2024
Comparison of clinicopathological features and treatment outcomes for cutaneous melanomas of the head and neck and melanomas arising at other sites: Implications for systemic therapyAndrew T Li, Jessie X Xu, Tyler R Blah, et al.
Cancers|December 5, 2019
Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic MelanomaRussell J Diefenbach, Jenny H Lee, Dario Strbenac, et al.
Annals of Surgical Oncology|May 27, 2024
Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 MelanomasAlec A Winder, Zoe Boyer, Sydney Ch'ng, et al.
Annals of Surgical Oncology|December 22, 2019
Regional Node Basin Recurrence in Melanoma Patients: More Common After Node Dissection for Macroscopic Rather than Clinically Occult Nodal DiseaseAbhineet Uppal, Stacey Stern, John F Thompson, et al.
Oncotarget|October 22, 2014
TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cellsSelina K Sutton, Jessica Koach, Owen Tan, et al.
The Journal of Investigative Dermatology|August 31, 2012
BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanomaGraham J Mann, Gulietta M Pupo, Anna E Campain, et al.
CA: a Cancer Journal for Clinicians|October 14, 2017
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manualJeffrey E Gershenwald, Richard A Scolyer, Kenneth R Hess, et al.
Melanoma Research|May 17, 2022
Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spreadAndrew T Li, Jia Miin Yip, Harsham Choksi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2018
CD103<sup>+</sup> Tumor-Resident CD8<sup>+</sup> T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 TreatmentJarem Edwards, James S Wilmott, Jason Madore, et al.
Pageof 57